Tekla Capital Management LLC Iovance Biotherapeutics, Inc. Transaction History

Tekla Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$20.35 - $26.63 $9.53 Million - $12.5 Million	-468,538 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$16.33 - $33.07 $850,090 - $1.72 Million	-52,057 Reduced 10.0%	468,538 $12.2 Million
Q1 2021 May 14, 2021	BUY	$28.67 - $52.59 $7.15 Million - $13.1 Million	249,522 Added 92.05%	520,595 $16.5 Million
Q2 2020 Aug 13, 2020	BUY	$27.21 - $41.0 $1.36 Million - $2.05 Million	50,000 Added 22.62%	271,073 $7.44 Million
Q1 2020 May 14, 2020	SELL	$19.54 - $38.85 $437,891 - $870,628	-22,410 Reduced 9.2%	221,073 $6.62 Million
Q4 2019 Feb 13, 2020	BUY	$17.95 - $29.41 $1.23 Million - $2.01 Million	68,471 Added 39.12%	243,483 $6.74 Million
Q3 2019 Nov 13, 2019	SELL	$17.99 - $26.0 $432,857 - $625,586	-24,061 Reduced 12.09%	175,012 $3.19 Million
Q2 2019 Aug 14, 2019	SELL	$9.78 - $24.52 $174,426 - $437,314	-17,835 Reduced 8.22%	199,073 $4.88 Million
Q3 2018 Nov 13, 2018	BUY	$11.25 - $17.7 $2.06 Million - $3.25 Million	183,513 Added 549.52%	216,908 $2.44 Million
Q2 2018 Aug 13, 2018	BUY	$12.45 - $16.95 $415,767 - $566,045	33,395 New	33,395 $427,000

323

239M

1.27M

1.68M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.52B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Tekla Capital Management LLC with notifications on news.